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Health,Wealth, and the 21st Century Cures Act
Americans are increasingly apprehensive about our
future, so it is inspiring when Congress produces legis-
lation intended toboth enhanceour health andexpand
our economy. The 21st Century Cures Act,1 recently
passed by theHousewith an impressive bipartisanma-
jority vote of 344 to 77, intends to accelerate themany-
step process of drug discovery and development, from
basic scientific research to clinical development to de-
livery, distribution, and ongoing monitoring. Among
other things, the legislationboostsNational Institute of
Health funding,dramatically speedsup theUSFoodand
Drug Administration (FDA) approval process, and aims
to make use of new information technology to better
monitor theperformanceofmedicalproductsafter they
reach themarket. This landmark bill now awaits a com-
parablepieceof legislationbeingdevelopedby theSen-
ate Health Education, Labor, and Pensions Committee.
Together, they will transform the biomedical ecosys-
temandprovide the foundation for thenext several de-
cades of innovative life-saving and health-enhancing
solutions for our nation and the world.
The genesis of this legislative effort was a growing
awarenessbypolicymakers onboth sides of the aisle in
Congress and in theWhiteHouse that scienceand tech-
nology are expanding opportunities in medicine at an
exponential pace, but our ecosystem for transforming
a discovery in the laboratory to a solution for patients
suffering and dying of disease is woefully inadequate.
Followinganoverwhelmingoutpouringof testimonyand
support by a broad cross section of stakeholders from
academia, industry, clinicians, and,most important, pa-
tients, the21stCenturyCuresActrepresentspublicpolicy
at its best—accelerating our understanding of the
genetic, molecular, and cellular mechanisms of dis-
eases while more quickly developing precise interven-
tions that are tailored and efficiently delivered to each
individual is the realization of the emerging era of per-
sonalizedmedicine.
Americans have invested heavily and enthusiasti-
cally in biomedical research over the years, motivated
by thehope forbetterhealth.Butwhathasnotbeenap-
parent is the fact that such investments will also dra-
matically improve our nation’s economy. Some have
raised concerns that such innovative medical products
will raise thecostsofhealthcareandwreckoureconomy.
The exact opposite is true. Providing effective targeted
new therapies that prevent or eliminate the morbidity
andmortality ofdiseasehasmultiplepositiveeffectson
growing the economy by improving human productiv-
ity and actually reducing the net costs of health care by
producing better outcomes and eliminating the costly
waste of an ineffective or excessive therapy.
The fact that the biomedical innovation stimulated
by 21st Century Cures will likely have enormous eco-
nomicbenefits is supportedbya largebodyof evidence.
Economists have estimated that the overall gains in lon-
gevity fromabout40to73yearsover the20thcentury—
evenwhenignoringequally impressivereductions inmor-
bidity—are equal in value to all growth inGDPper capita,
from about $5000 to $40 000 per capita during that
century. Inthissense, thegrowth in lifespan itselfwasper-
haps the most important economic achievement of the
past 100 years. Biomedical innovation and our in-
creasedunderstandingofdiseaseswasan importantpart
of thatachievement.Forexample, the incremental gains
achieved in the so-called war on cancer declared in 1971
yielded benefits to Americans estimated to be about 6
times the costs spent on the research, a huge economic
success despite the negative rhetoric and popular de-
bate surrounding this war. More importantly, research
across many diseases, such as human immunodefi-
ciency virus (HIV), heart disease, as well as cancer, has
shown thatwhen new therapies are introduced into the
market, patients—not manufacturers—capture most of
their economic value (on average, 80%-95%). As an
example, a future stem cell therapy that could even par-
tially restore or delay the need for hemodialysis or kid-
ney transplantsproducescost savings tosociety, andthe
value topatients—improved longevity, vitality, andearn-
ings—would dwarf the profits of the innovators.
For those concerned about 21st Century Cures ini-
tiatives increasing health care costs, it is important to
distinguish the bill’s impact on the price of health as
opposed to the price of health care. Before a new
therapy is introduced, the price of better health is
effectively infinitely expensive for patients who do not
respond to existing standards of care; they can’t go
anywhere to buy more health at any price. If the legis-
lation creates genuinely new and effective therapies,
this always lowers the price of health. To illustrate,
before the breakthrough highly active antiretroviral
therapy (HAART) for HIV in 1996, HIV-positive indi-
viduals could not buy longer lives anywhere at any
price. The introduction of the effective HIV cocktails
therefore dramatically reduced the price of longer lives
for patients with HIV. These are the types of price cuts
21st Century Cures will offer. Moreover, new innova-
tions have the important economic effect of providing
more competition between manufacturers, further
lowering the price of health.
An even more important objective of 21st Century
Cures is to not only lay the foundation on which future
biomedical innovation and economic growth will
be built but also attract increased investments by the
private sector. The current bounty of new cancer
therapeutics—22 FDA-approved cancer drugs in 2013
and 2014—is a direct result of the 1971 National
Cancer Act and more than 4 decades of sustained
government-sponsored research and development
(R & D). The fact that the private sector now invests
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even more in oncology-related R & D than the government under-
scores the virtuous cycle created by public funding of basic scien-
tific research. By supporting advances in our understanding of can-
cer biology, the National Cancer Institute has provided the
biopharmaceutical industry with clear targets, mechanisms, and
pathways for developing breakthrough therapeutics. In areas
where such support is lacking, we see corresponding gaps in
knowledge and, consequently, private-sector investment. For
example, we have yet to direct the same type of government fund-
ing toward neurodegenerative diseases, such as Alzheimer disease
and dementia; hence, it should come as no surprise that not a
single new Alzheimer drug has been approved by the FDA in over a
decade, and several big pharmaceutical companies have scaled
back or shut down their Alzheimer therapeutics programs.
If passed, the 21st Century Cures Act will be a milestone in US
legislation ofmedical innovation, giving us the opportunity to save
countless lives in the coming years around the world. The over-
whelming support for21stCenturyCures in theHousemustbe tem-
peredby the fact that nothingwill happenuntil the Senate takes up
this issue and both crafts and passes its own version of the legisla-
tion. An unnecessary delay that results in the demise of the House
effortwould be tragic, not just because itwould be amajor setback
to patients and their families, but also because of the missed op-
portunity toaccelerateeconomicgrowth forallAmericans in thisun-
precedented era of breakthroughs in biomedicine. In an industry
catalyzedby recent scientificbreakthroughsbutchallengedbycom-
plexity, this legislation will reenergize scientists, clinicians, inves-
tors, and other stakeholders, and is just what the doctor ordered.
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